



QFR Predicts the Incidence of Long-Term Adverse
Events in Patients with Suspected CAD:
Feasibility and Reproducibility of the Method
Andrea Buono † , Annika Mühlenhaus †, Tabitha Schäfer, Ann-Kristin Trieb, Julian Schmeißer,
Franziska Koppe, Thomas Münzel , Remzi Anadol and Tommaso Gori *
Kardiologie I, Universitätsmedizin Mainz and DZHK Standort Rhein-Main, 55128 Mainz, Germany;
andrebuo@hotmail.com (A.B.); annika.muehlenhaus@web.de (A.M.); tabitha.schaefer@gmx.de (T.S.);
ann-kristin.trieb@gmx.de (A.-K.T.); julian.schmeisser@t-online.de (J.S.);
franziska.koppe@unimedizin-mainz.de (F.K.); tmuenzel@uni-mainz.de (T.M.);
remzi.anadol@unimedizin-mainz.de (R.A.)
* Correspondence: tomgori@hotmail.com
† These authors contributed equally to this work.
Received: 26 December 2019; Accepted: 10 January 2020; Published: 14 January 2020


Abstract: AIMS: We evaluate feasibility and reproducibility of post hoc quantitative flow ratio (QFR)
measurements and their prognostic predictive power during long-term follow-up. METHODS AND
RESULTS: Between 2010 and 2012, 167 patients without angiographic evidence of significant stenoses
were enrolled in a prospective registry. Of these patients, 96% presented 7 years follow-up data.
QFR was measured post hoc by three certified investigators. QFR analysis was feasible in 71% of
left anterior descending (LAD), 72% of left circumflex (LCX), and 61% of right (RCA) coronaries
for a total of 350 measurements repeated in triplicate. Coefficients of variation were 2.1% for RCA
and LCX, and 2.8% for the LAD (quartile coefficients of dispersion respectively 1.5, 1.4, and 1.3).
QFR ≤0.80 was recorded in 25 patients (27 vessels, in 74% of the cases LAD). A total of 86 major
adverse cardiovascular and cerebrovascular events were observed in 76 patients. QFR ≤0.80 in at least
one of the three vessels was the strongest predictor of events (HR 3.14, 95%CI 1.78–5.54, p = 0.0001).
This association was maintained in several sensitivity analyses. CONCLUSIONS: QFR reproducibility
is acceptable, even when analysis is performed post hoc. A pathological QFR is not rare in patients
without angiographic evidence of significant stenosis and is a predictor of incident events during
long-term follow-up. Condensed Abstract: In a post hoc analysis of 167 patients without evidence of
angiographic significant stenosis, the presence of QFR value ≤0.80 in at least one of the three coronary
vessels showed to be the strongest predictor of major adverse cardiovascular and cerebrovascular
events during long-term follow-up. QFR reproducibility have been shown to be acceptable among
experienced operators.
Keywords: fractional flow reserve; coronary artery disease; coronary interventions; Quantitative
flow reserve
1. Introduction
Invasive coronary angiography is the most commonly used method for the identification of
coronary artery disease (CAD) in patients with high suspicion. However, angiography alone does
not accurately reflect the hemodynamic relevance of coronary lesions. Several tools have been
developed to overcome this limitation, among which fractional flow reserve (FFR) and instantaneous
wave-free ratio (iFR) represent the most frequently adopted. Given their reliability in the prediction of
cardiovascular events and consequently in guiding the decision whether to perform percutaneous
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coronary intervention (PCI) [1–8], the use of these methods is recommended as Class IA in the current
guidelines on myocardial revascularization [9]. Despite the indisputable benefit of these functional
indexes, their use increases the invasiveness and the cost of procedure, and their penetration remains
unfortunately low.
In the last years, a novel approach enabling rapid computation of the hemodynamic relevance of
a stenosis based on three-dimensional quantitative coronary angiography and fluid dynamic algorithms
has been developed; the index derived from this analysis, named quantitative flow ratio (QFR), has
been validated against FFR in multiple studies [10–13]. QFR has shown to have a significantly higher
sensitivity and specificity compared with quantitative coronary analysis (QCA) [14]. Increasing evidence
supports its applicability in different conditions. In fact, its usefulness has been demonstrated not
only in the context of native coronary artery stenosis, including small vessel disease [15], but also in
particular lesion settings, such as in-stent restenosis [16]. Moreover, its use can be applied immediately
after PCI, in order to confirm the hemodynamic results of the revascularization and eventually to
guide further treatment, as recently demonstrated in the HAWKEYE study [17]. QFR is also a valuable
tool in the context of acute coronary syndrome: an incomplete revascularization detected by QFR has
been associated with a higher rate of cardiovascular events in an ST elevation myocardial infarction
(STEMI) population [18].
Despite these promising data, several issues remain to be clarified before QFR is introduced in
clinical practice. First, QFR requires high-quality end-diastolic images of the whole segment under
exam in at least two angiographic views with at least 25◦ angle separation, which might not be
available from standard routine angiographies not performed for the purpose of QFR analysis. Second,
it remains unclear to what extent QFR allows identifying lesions requiring treatment that are otherwise
not found at angiography. Finally, evidence concerning the prognostic predictive power of QFR during
long-term follow-up is emergent.
2. Methods
2.1. Goal of the Study and Study Design
We set out to assess the feasibility and reproducibility of QFR measurements performed post hoc in
standard angiographic exams. Further, the goal of the study was to investigate whether the assessment
of QFR in patients with an angiographic diagnosis of nonrelevant coronary artery disease allows
identification of hemodynamically relevant stenosis that were missed at angiography, and whether
vessels with abnormal QFR left untreated are associated with worse patients′ prognosis.
This single-center registry enrolled consecutive patients with suspected coronary artery disease in
whom the presence of relevant stenosis was excluded at angiography. Follow-up data were collected
prospectively. The study complied with the Declaration of Helsinki for investigation in human beings
and was approved by the ethics committee of the Landesärztekammer Rheinland-Pfalz. All patients
gave written informed consent. The study is registered in clinicaltrials.gov as NCT01787370.
2.2. Study Population and Endpoint Definition
Consecutive patients (≥18 years old) with suspected coronary artery disease (stable angina or
stable angina equivalent) undergoing coronary angiography were consecutively enrolled between
January 2010 and February 2012 in the Flow-Mec registry, a study designed to prospectively investigate
novel early and long-term determinants of cardiac and cerebrovascular prognosis [19]. From this
database, consecutive patients with mild to moderate (10–70%) lesions at angiography were included
in the current analysis: the presence of a stenosis judged to be significant at angiography and treated
ad hoc or scheduled for subsequent revascularization, a previous history of coronary artery bypass
grafting (CABG), the presence of unstable symptoms (worsening angina or rest angina within one
month), a myocardial infarction (MI) episode or cardiac catheterization within three months before
angiography and presence of chronic total occlusions were exclusion criteria.
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The primary endpoint of the Flow-Mec study was the incidence of major adverse cardiovascular
and cerebrovascular events (MACCE), defined as a composite of all-cause mortality, MI (both non
ST-segment elevation and ST-segment elevation MI), cerebrovascular stroke, and any incident coronary
artery revascularization (both surgical and/or percutaneous). Secondary endpoints included target
vessel failure (TVF), defined as composite of cardiovascular death, target vessel myocardial infarction,
and target vessel revascularization, as well as each separate component of the composite endpoint.
The incidence of events was assessed with in-person or telephone visits. All events were validated
against original clinical documents.
2.3. Data Management and Analysis
QFR was measured from original coronary angiography DICOM files stored in the hospital′s
picture archiving and communication system. Angiograms were performed using a Philips
AlluraClarity (Philips Medical Systems, Amsterdam, the Netherlands) and stored in Xcelera (Philips
medical systems). Three certified investigators (A.M., T.S., and A.T.) independently analyzed each
coronary vessel using QFR Medis Suite system (Medis, Leiden, the Netherlands) following the
manufacturer’s instructions. Investigators were unaware of the patients’ follow-up data.
2.4. Statistics
Descriptive statistics are reported as mean ± SD, median (interquartile range), or frequencies
(%), as appropriate. Normal distribution was tested by inspection of the Q–Q plots. Coefficients of
variation and quartile coefficients of dispersion among the three investigators′ measurements were
determined to assess the repeatability of the measurements.
The primary endpoint of the study was to test whether QFR is a predictor of MACCE during 7 years
follow-up in multivariable analysis. A list of all prespecified parameters included in univariate analysis
is provided in Table 1. Parameters with a univariate p < 0.05 were entered in multivariable analysis.
Table 1. Study population characteristics. Comparison between population subgroups divided





(25) All Patients p-Value
Age, years ± SD 65.1 ± 11.3 66 ± 11.5 65.1 ± 11.3 0.70
Male sex, n (%) 87 (66.4) 21 (84.0) 108 (70.0) 0.13
Atrial Fibrillation, n (%) 20 (15.3) 7 (28.0) 27 (17.3) 0.22
Chronic obstructive pulmonary
disease, n (%) 12 (9.1) 5 (20.0) 17 (10.9) 0.22
Diabetes mellitus, n (%) 21 (16) 6 (24.0) 27 (17.3) 0.51
Family history of CAD, n (%) 36 (27) 4 (16.0) 40 (25.6) 0.37
Dyslipidemia, n (%) 72 (55) 16 (64.0) 88 (56.4) 0.56
Hypertension, n (%) 104 (79.4) 21 (84.0) 125 (80.1) 0.78
Chronic kidney disease, n (%) 9 (6.9) 1 (4.0) 10 (6.4) 0.92
Obesity, n (%) 42 (32) 7 (28.0) 49 (31.4) 0.85
Smoking, n (%) 64 (48.8) 12 (48.0) 76 (48.7) 0.92
Severe valvular heart disease, n (%) 7 (5.3) 0 (0.0) 7 (4.5) -
Previous PCI, n (%) 52 (39.7) 16 (64.0) 68 (43.6) 0.04
Previous MI, n (%) 32 (24.4) 5 (20.0) 37 (23.7) 0.82
Left ventricular ejection fraction
<30%, n (%) 5 (3.8) 2 (8.0) 7 (4.5) 0.60
ACEi and/or ARBs, n (%) 90 (68.7) 20 (80) 110 (70.5) 0.40
Aspirin, n (%) 89 (67.9) 19 (76) 108 (69.2) 0.56
Beta-Blockers, n (%) 79 (60.3) 18 (72) 97 (62.1) 0.36
Calcium Channel Blockers, n (%) 31 (23.7) 8 (32.0) 39 (25) 0.49
Nitrates, n (%) 21 (16) 4 (16.0) 25 (16.1) 0.78
Statin, n (%) 70 (53.4) 19 (76.0) 89 (57.4) 0.07
CAD: coronary artery disease. ACEi: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers.
Chronic kidney disease: GFR < 60 mL/min. CABG: coronary by-pass. MI: myocardial infarction; PCI: percutaneous
coronary intervention. SD: Standard deviation.
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Pairwise comparisons were made with Student t-test or Chi-squared tests, as appropriate.
Hazard ratios (HR) were calculated with Cox proportional hazards regression. For survival analysis,
Kaplan–Meyer survival curves were drawn. A two-sided p value of <0.05 was considered significant
for the primary endpoint, all other analyses are exploratory. Statistical analysis was performed with
MedCalc version 13.0 (Mariakerke, Belgium).
3. Results
3.1. Feasibility and Clinical Characteristics
The study flow is shown in Figure 1. A total of 167 patients meeting the inclusion and exclusion
criteria were identified from the Flow-Mec database, and their characteristics are presented in Table 1.
The mean age of study population was 65 ± 11.3 years, 70% patients were male, and 17.3% had
diabetes. Of the 501 vessels, 151 (30%) could not be analyzed due to absence of adequate high-quality
end-diastolic frames containing the whole vessel length in at least two projections and separated by
an angle >25◦, without overlap at the lesion segment of interest, excessive foreshortening, or insufficient
contrast filling. In 11 patients, none of the three vessels could be analyzed. In sum, QFR of the left
anterior descending (LAD) could be analyzed in 122 (73%) patients, QFR of the left circumflex (LCX)
could be analyzed in 123 (74%), and the right coronary artery (RCA) could be analyzed in 105 (63%).
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Figure 1. Study Flow Chart. QFR: Quantitative Flow Reserve; QCA: Quantitative Coronary Analysis;
LAD: Left Anterior Descending Artery; LCX: Left Circumflex Artery; RCA: Right Coronary Artery.
3.2. Reproducibility
Each QFR analysis was performed by three independent certified operators for a total of
1050 measurements. The mountain plots are presented in Supplemental Figure S1. The coefficient of
variation was 2.8% for QFR measurements in the LAD, 2.1% for the LCX and RCA. The corresponding
quartile coefficients of dispersion were 1.5, 1.4, and 1.3.
3.3. QFR Analysis
Examples of QFR analyses are presented in Figure 2. The mean QFR values were 0.91 ± 0.07 for
the LAD, 0.96 ± 0.04 for the LCX, and 0.96 ± 0.05 for the RCA. There were 27 vessels (7.7%) with QFR
≤0.80 (LAD in 20 patients, LCX in 3, and RCA in 4). Two patients had a pathological QFR in two
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vessels (LAD and LCX in one patient, LCX and RCA in the other). The remaining 131 patients had QFR
>0.80 in all vessels analyzed. Patients with at least one vessel with QFR ≤0.80 had more frequently
a history of PCI (64% vs. 39.7%, p = 0.04). Otherwise, there was no difference between patients with at
least one vessel with QFR ≤0.80 and those without pathological QFR values. Table 2 summarizes the
main angiographic findings. The degree of coronary stenosis at quantitative angiography (QCA) was
significantly higher in the group of patients with pathological QFR, both in terms of diameter (DS%)
and area stenosis (AS%). Despite these differences, no lesion in either group was angiographically
severe (>75%) at QCA analysis. Lesion length was longer in the LCX (24.3 ± 16.0 vs. 14.6 ± 8.2 mm,
p = 0.0001), and reference vessel diameter was smaller in the LAD (2.3 ± 0.6 vs. 2.6 ± 0.7 mm, p = 0.04)
in patients with QFR ≤0.80. QFR analysis showed differences for all three vessels.
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Table 2. Angiographic characteristic of patients presenting with QFR >0.80 in all the analyzed vessel








Lesion length LAD ± SD, mm (n) 18.87 ± 11.25 (97) 22.52 ± 12.34 (25) 0.16
Lesion length RCA ± SD, mm (n) 14.67 ± 7.71 (85) 17.39 ± 10.91 (20) 0.20
Lesion length LCX ± SD, mm (n) 14.63 ± 8.19 (103) 24.26 ± 15.99 (20) 0.0001
DS% LAD ± SD, (n) 33.55 ± 7.64 (97) 46.14 ± 7.31 (25) <0.0001
DS% RCA ± SD, (n) 31.98 ± 7.97 (85) 39.47 ± 11.25 (20) 0.0008
DS% LCX ± SD, (n) 33.43 ± 7.64 (103) 41.16 ± 10.00 (20) 0.0001
AS% LAD ± SD, (n) 36.10 ± 11.16 (97) 50.43 ± 11.78 (25) <0.0001
AS% RCA ± SD, (n) 36.48 ± 12.12 (85) 46.02 ± 15.47 (20) 0.0034
AS% LCX ± SD, (n) 34.99 ± 10.71 (103) 43.76 ± 14.41 (20) 0.002
RVD LAD ± SD, mm (n) 2.56 ± 0.65 (97) 2.26 ± 0.58 (25) 0.04
RVD RCA ± SD, mm (n) 2.93 ± 0.67 (85) 3.10 ± 0.60 (20) 0.30
RVD LCX ± SD, mm (n) 2.53 ± 0.58 (103) 2.37 ± 0.63 (20) 0.26
QFR LAD, (n) 0.93 ± 0.05 (97) 0.75 ± 0.10 (25) <0.0001
QFR RCA, (n) 0.97 ± 0.04 (85) 0.92 ± 0.09 (20) 0.0001
QFR LCX, (n) 0.97 ± 0.04 (103) 0.91 ± 0.08 (20) 0.0001
RVD: reference vessel diameter; DS%: diameter stenosis%; AS%: area stenosis%.
3.4. Follow-Up
Seven years follow-up data were available in 96% of the patients.
3.5. MACCE
A total of 86 events in 76 patients were observed at 2334 (1846–2580) days. There were 32 deaths
(10 of cardiac origin), 5 cerebrovascular strokes, 15 new MI, and 34 repeated revascularizations (30 PCI
and 4 CABG).
In univariate analysis (Table 3), older age (HR 1.023, 95%CI 1–1.04, p = 0.03), male sex (HR
2.24, 95%CI 1.27–3.94, p = 0.005), chronic kidney disease (CKD) (HR 2.27, 95%CI 1.09–4.72, p = 0.03),
a previous history of PCI (HR 2.03, 95%CI 1.28–3.20, p = 0.0025), and the presence of QFR ≤0.80 in
at least one of the three vessels (HR 3.42, 95%CI 2.06–5.67, p < 0.0001) were predictors of MACCE.
Among QCA parameters, AS% and DS%, but not RVDs and lesion length, showed an association
with MACCE.
Seven variables were entered in multivariate analysis (Table 4). Only a previous history of PCI
(HR 1.90, 95%CI 1.15–3.15, p = 0.0134), chronic kidney disease (HR 2.81, 95%CI 1.26–6.26, p = 0.0118),
and the presence of QFR ≤0.80 in at least one of the three vessel (HR 3.14, 95%CI 1.78–5.54, p = 0.0001)
were predictors of long-term MACCE incidence. The Kaplan–Meier survival curves describing the
impact of pathological QFR are shown in Figure 3. The association between QFR and events was
driven mostly by repeat revascularizations (HR 0.22, 95%CI 0.03–0.23, p < 0.0001), while the association
with myocardial infarction (HR 0.42, 95%CI 0.07–1.39, p = 0.1258), stroke (p = 0.432), and death (HR
0.85, 95%CI 0.30–2.31, p = 0.7335) were not significant.
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Table 3. Long-term MACCE (major adverse cardiovascular and cerebrovascular events) predictors at
univariate analysis.
Parameter HR 95%CI p-Value
Age 1.02 1.00–1.05 0.03
Diabetes 1.42 0.82–2.46 0.21
Family history 0.95 0.56–1.62 0.86
Dyslipidemia 0.92 0.58–1.45 0.72
Arterial Hypertension 1.06 0.60–1.86 0.85
Obesity 1.12 0.69–1.80 0.65
Sex category 2.24 1.27–3.94 0.005
Smoke 0.96 0.61–1.51 0.85
Atrial Fibrillation 1.41 0.82–2.42 0.21
Known CAD 2.15 1.30–3.55 0.002
COPD 1.53 0.81–2.90 0.20
Severe LV dysfunction 1.53 0.62–3.79 0.36
CKD 2.27 1.09–4.73 0.03
Multivessel CAD 2.55 1.62–4.02 0.0001
Previous PCI 2.03 1.28–3.20 0.003
Previous MI 1.51 0.92–2.47 0.11
Severe valvular disease 1.70 0.62–4.66 0.30
ACEi or ARBs 1.22 0.72–2.07 0.47
ASA 1.63 0.95–2.79 0.08
BB 1.58 0.96–2.60 0.07
CCB 1.06 0.63–1.78 0.83
Nitrates 0.93 0.50–1.71 0.81
Statins 1.52 0.94–2.45 0.09
Lesion length LAD 1.01 0.99–1.03 0.36
Lesion length RCA 1.03 1–1.06 0.10
Lesion length LCX 1.02 1–1.04 0.09
QFR LAD ≤ 0.80 3.08 1.73–5.50 0.0001
QFR RCA ≤ 0.80 3.24 1.17–8.97 0.02
QFR LCX ≤ 0.80 - - -
RVD LAD 0.72 0.47–1.11 0.14
RVD RCA 1.01 0.65–1.56 0.98
RVD LCX 1.08 0.70–1.67 0.72
AS% LAD 1.03 1.00–1.05 0.02
AS% RCA 1.03 1.01–1.06 0.002
AS% LCX 1.02 1–1.04 0.07
DS% LAD 1.04 1.01–1.07 0.0076
DS% RCA 1.05 1.02–1.08 0.001
DS% LCX 1.03 1–1.06 0.07
QFR LAD 0.01 0.001–0.09 0.0001
QFR RCA 0.001 0.00–0.03 0.0003
QFR LCX 0.003 0.00–0.33 0.02
≥1-vessel QFR ≤0.80 3.42 2.06–5.67 <0.0001
COPD: chronic obstructive pulmonary disease; LV: left ventricle; CKD: chronic kidney disease; ASA: Acetylsalicylic
Acid; BB: Beta-blockers; CCB: Calcium channel blockers.
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Table 4. Long-term MACCE predictors at multivariate analysis.
Parameter HR 95%CI p-Value
Age 1.02 0.99 to 1.04 0.19
Sex 1.44 0.78 to 2.67 0.24
CKD 2.81 1.26 to 6.26 0.01
Previous PCI 1.90 1.15 to 3.15 0.01
Valvular disease 1.14 0.55 to 2.35 0.73
≥1-vessel QFR ≤0.80 3.14 1.78 to 5.54 0.0001
Overall model fit: Chi-Square 42.80, p < 0.00001.
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3.6. Secondary Endpoints
The predictive role of QFR ≤0.80 was maintained in a subanalysis limited to patients without
a prior history of revascularization. In these patients, QFR ≤ .80 was associated with a 3.24-fold
increase in risk of long-term MACCE in this subgroup of patients (HR 3.24, 95%CI 1.40–7.48, p = 0.006).
The corresponding Kaplan–Meier curve is presented in Supplemental Figure S2. Similarly, a sensitivity
analysis excluding patients with kidney failure confirmed the predictive power of QFR (HR 4.26,
95%CI 2.52–7.20, p < 0.001).
Figure 4 shows the receiver operating characteristic (ROC) curves for QFR in individual coronary
arteries. This analysis showed a stronger association for the QFR values assessed in the LAD and the
RCA (area under the curve of the LAD: 0.65, 95%CI 0.56–0.73, p = 0.002; RCA: 0.67; 95%CI 0.57–0.76;
p = 0.001), whereas the QFR measured in the LCX showed a weaker association (area under the curve
0.54, 95%CI 0.44–0.63, p = 0.50). The thresholds associated with the best combination of sensitivity
and specificity were QFR ≤0.85 in the LAD (sensitivity: 42.1% (95%CI 29.1–55.9%), specificity: 84.1%
(95%CI 72.7–92.1%), positive predictive value 2.65, negative predictive value 0.69), while a value ≤0.80
demonstrated a very high specificity but a low sensitivity (sensitivity: 29.8% (95%CI 18.4–43.4%),
specificity: 95.2% (95%CI 86.7–99%), positive predictive value 6.26, negative predictive value 0.74).
In analogy, QFR≤0.96 in the RCA was associated with the best combination of sensitivity and specificity
(sensitivity 49%, 95%CI 34.8–63.4%; specificity 79.6%, 95%CI 66.5–89.4%) positive predictive value 2.41,
negative predictive value 0.64).
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(C). AUC: area under the curve.
During follow-up, 25 TLFs of the LAD occurred. Incident TLF during follow-up identified patients
with a significantly lower value of LAD QFR at index (0.83, 95%CI 0.71–0.91 vs. 0.90, 95%CI 0.86–0.97;
p = 0.002). Figure 5 shows the Kaplan–Meier curves for cut-off values of LAD QFR ≤0.80 and ≤0.90.
With both cut-offs, a pathological QFR of the LAD was associated with incident TLF.
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Figure 5. Kaplan–Meier curves for LAD-TLF assuming a cut-off LAD QFR value ≤0.80 (A) and ≤ 0.90 (B).
Finally, Supplemental Figures S3 and S4 show the curves describing the association of QFR ≤0.80
and QFR ≤0.90 with individual endpoints. For both QFR thresholds, there was an association with
incident revascularizations (p < 0.0001 for QFR ≤0.80, p = 0.0013 for QFR ≤0.90), but not for death or
incident myocardi l infarction.
4. Discussion
We report on the feasibility, reproducibility, and predictive power of QFR in a group of patients
enrolled in the Flow-Mec study, a prospective registry on the predictors of ischemic events in
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patients undergoing coronary angiography. The main findings of this study include the following:
1. QFR assessments are feasible in only 70% of coronary angiograms when these are not performed
for the purpose (and therefore not respecting the specific criteria) of QFR measurements. 2. The
reproducibility of these assessments is good, and similar to that reported in previous QFR studies. 3.
Findings of pathological QFR are not rare (7.7% of all vessels measured) and are more frequent in
the LAD than in LCX and RCA. In our population, 16% of patients affected by intermediate coronary
artery stenosis judged angiographically not significant presented a pathological QFR value at off-line
analysis. This aspect corroborates the importance to perform a more routinely use of functional tools
in the context of intermediate coronary stenosis. 4. The presence of a QFR ≤0.80 is associated with
a 3-fold increase in the risk of major adverse cardiovascular and cerebrovascular events, principally
driven by an increased risk of target vessel failure and revascularization. Importantly, the survival
curves diverge already during the first months after the index catheterization. In our population, also
CKD (HR 2.81, 95%CI 1.26–6.26, p = 0.01) and a previous history of PCI (HR 1.90, 95%CI 1.15–3.15,
p = 0.01) have been associated with a higher risk of long-term MACCE, despite their predictive values
being lower compared with QFR ones (HR 3.14, 95%CI 1.78–5.54, p = 0.0001). Interestingly, in the
meantime, other variables such as obesity and received anti-ischemic treatment did not correlate with
the risk of MACCE, suggesting that prognosis in patients affected by intermediate coronary stenosis
is determined by multiple factors, related not only to a patient’s classical clinical risk profile and
medications, but also to plaque’s characteristics and rheological aspects.
Invasive methods to assess the hemodynamic significance of coronary artery stenoses are
associated with improved short- and long-term outcomes, principally driven by a reduced incidence
of revascularization and target vessel myocardial infarction [1–3]. Despite their advantages,
the penetration of these invasive techniques remains low due to cost or logistic considerations,
limited access, and a perceived increased risk associated with intracoronary procedures and the
administration of vasodilators. Further, an intrinsic disadvantage of these invasive procedures is
that they need to be performed at the time of catheterization, and a post hoc reassessment of the
hemodynamic relevance of a stenosis is clearly not possible. QFR assessment has the advantage of
a reduced invasiveness, no additional risks beyond those of invasive catheterization, and that it allows
off-line re-evaluation of stenosis any time after conclusion of the angiogram. Evidence from a recent
retrospective study demonstrates that QFR predicts the incidence of major adverse cardiovascular
events (MACE) during a 2.2 years follow-up [20]. The current manuscript expands on these data,
providing evidence of the feasibility, reproducibility, and clinical relevance of QFR data during a 7 years
follow-up. Taken together, the current data validate the use of QFR also for off-line, post hoc decisions
for the interpretation of coronary angiograms, even though the feasibility of the measurements is
relatively low (70%) in angiograms not performed according to the specific QFR requirements. Our data
reproduce the results of the large FFR trials, providing further evidence that lesions and patients at risk
may be identified by measuring the hemodynamic relevance of coronary stenoses even when, based on
angiography alone, a decision against intervention has been taken.
Limitations
Our study has several limitations. First, angiograms were performed between 2010 and 2012 (when
QFR was not yet available), and although follow-up was prospective, Digital Imaging and Comunication
in Medicine (DICOM) movies were retrospectively analyzed. Although this methodological limitation
needs to be acknowledged, QFR was not available at the time of patient inclusion, and it would have
been ethically unacceptable to prospectively study the outcome of patients in whom a pathological
QFR had been found. The feasibility of post hoc QFR measurements was one of the endpoints of the
study. QFR analysis was not possible in about 30% of the vessels, and no conclusion can be taken
regarding the presence of relevant stenoses in these vessels and how these affected patient prognosis.
Also, side branches were not measured, and QFR has not been validated for ostial lesions. Second,
some patients had a history of prior PCI, which also may influence the results and the association
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between events and stenosis at index. A sensitivity analysis performed after exclusion of these
patients confirmed however the main findings of the study. QFR has not been validated in by-pass
recipients, and these patients were therefore excluded from the present analysis. The prespecified
primary endpoint of Flow-Mec was MACCE, while previous FFR/iFR studies focused on MACE or TLF.
Exploratory analyses using these endpoints were however consistent with the main results. Finally,
adherence to medical therapy during follow-up was not assessed.
5. Conclusions
QFR analysis is feasible in 70% of routinely performed angiograms. QFR is a reproducible and
effective diagnostic tool that improves, without additional risks, the ability of angiography to identify
significant coronary artery stenoses. A value of QFR ≤0.80 detected in at least one coronary vessel
predicts a 3-fold higher risk to develop a major cardiovascular and cerebrovascular adverse event
during long-term follow-up.
6. Impact on Daily Practice
QFR is a valuable and reproducible tool to assess hemodynamic severity of coronary artery
stenosis. QFR ≤0.80 in at least one of the three coronary vessels should be considered as a prognostic
risk factor to develop long-term follow-up major adverse cardiovascular and cerebrovascular events.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/1/220/s1,
Supplemental Figure S1: Mountain Plots of QFR reproducibility, Supplemental Figure S2: QFR Kaplan–Meier
event-free survival curves of patients without a prior history of revascularization, Supplemental Figure S3:
Kaplan–Meier curves describing event-free survival of QFR ≤ 0.80 concerning individual endpoints, Supplemental
Figure S4: Kaplan–Meier curves describing event-free survival of QFR ≤ 0.90 concerning individual endpoints.
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Abbreviations
AS% percentage of Area Stenosis
CABG Coronary Artery Bypass Grafting
CAD Coronary Artery Disease
CKD Chronic Kidney Disease
CI Confidence Interval
DS% percentage of Diameter Stenosis
FFR Fractional Flow Reserve
HR Hazard Ratio
iFR instantaneous wave-free Ratio
LAD Left Anterior Descending Artery
LCX Left Circumflex Artery
MACE Major Adverse Cardiovascular Events
MACCE Major Adverse Cardiovascular and Cerebrovascular Events
MI Myocardial Infarction
NSTEMI Non-ST Elevation Myocardial Infarction
PCI Percutaneous Coronary Intervention
QCA Quantitative Coronary Analysis
QFR Quantitative Flow Reserve
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RCA Right Coronary Artery
ROC Receiver Operating Characteristic
RVDs Reference Vessel Diameters
SD Standard Deviation
STEMI ST Elevation Myocardial Infarction
TLF Target Lesion Failure
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